Aryx announce favorable QT results with 5HT4 agonist ATI-7505 « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
August 2008

M T W T F S S

« Jul Sep »

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

Aryx announce favorable QT results with 5HT4 agonist ATI-7505

Posted on August 7, 2008 by crimsoncanary

ARYx Therapeutics have announced that its 5HT4 agonist ATI-7505 had demonstrated a favorable cardiotoxicity profile in a thorough QT study.

Filed under: Uncategorized | Tagged: 5-HT4, 5HT4, agonist, ATI-7505, ATI7505

« Merck publish series of Bradykinin B1 Receptor Antagonists GSK publish series of Tricyclic Azepine derivative 5HT6 antagonists »

Leave a Reply